2-phenyl-3,5,6,7-tetrahydro-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one | 18678-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2-phenyl-3,5,6,7-tetrahydro-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one
• 英文别名: 4-Hydroxy-2-phenyl-5,6-trimethylen-thieno<2,3-d>pyrimidin；4H-Cyclopenta(4,5)thieno(2,3-d)pyrimidin-4-one, 1,5,6,7-tetrahydro-2-phenyl-；10-phenyl-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9-trien-12-one
• CAS: 18678-30-3
• 化学式: C₁₅H₁₂N₂OS
• 分子量: 268.339
• InChiKey: AAIHOQORNARFIA-UHFFFAOYSA-N

物化性质

• 熔点：
  210 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  493.9±55.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-phenyl-3,5,6,7-tetrahydro-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one 在 草酰氯 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 2-phenyl-4-hydrazino-5,6,7-trihydrocyclopenta[b]thieno[2,3-d]pyrimidine
  参考文献：
  名称：

  一些新型三唑并噻吩并嘧啶的合成和抗菌活性。

  摘要：

  一系列新颖的5-取代的1,2,4-三唑[4,3-c] 8,9,10-三氢环戊/ 8,9,10,11,12-五氢环庚[b]噻吩并[3，已经合成了2-e]嘧啶-3-硫酮。通过加热2-取代-5，制备中间体4-氯-2-取代-5,6,7-三氢环戊/ 5,6,7,8,9-五氢环庚[b]噻吩并[2,3-d]嘧啶。 ，6,7-三氢环戊5 / 5,6,7,8,9-五氢环庚[b]噻吩并[2,3-d]嘧啶-4 [3H]-与草酰氯。噻吩并[2,3-d]嘧啶-4 [3H]-是通过新颖的，微波辅助的，无溶剂的合成路线在迄今文献中从未报道过的由噻吩的邻氨基酯制备的碱性条件下制备的。无需进一步纯化即可将氯代衍生物肼化，得到2-取代的4-肼基-5,6,7-三氢环戊5 / 5,6,7,8,9-五氢环庚[b] thieno [2,3-d]嘧啶类。这些化合物用二硫化碳环化，以定量收率得到标题化合物。使用氨苄青霉素作为标准品，针对

  DOI：

  10.1248/cpb.55.557
• 作为产物：
  描述：

  环戊酮 在 盐酸 、 1,2,3,4,5,6,7,8-八硫杂环辛烷 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 60.0h， 生成 2-phenyl-3,5,6,7-tetrahydro-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one
  参考文献：
  名称：

  发现基于Thieno [2,3-d]嘧啶的异羟肟酸衍生物为含溴结构域的蛋白4 /组蛋白去乙酰化酶双重抑制剂，可导致大肠癌细胞自噬。

  摘要：

  含溴结构域的蛋白质4（BRD4）和组蛋白脱乙酰基酶（HDAC）都是癌症和其他慢性疾病中有吸引力的表观遗传学靶标。基于整合的基于片段的药物设计，合成以及体外和体内评估，发现了一系列新型的基于噻吩并[2,3 - d ]嘧啶的异羟肟酸衍生物，作为选择性的BRD4-HDAC双重抑制剂。化合物17c是BRD4和HDAC的最有效抑制剂，其IC 50值在纳摩尔水平以及c-Myc的表达水平，并增加组蛋白H3的乙酰化。而且17c通过诱导自噬细胞死亡，对大肠癌（CRC）细胞的增殖具有抑制作用。它还在大鼠中具有良好的药代动力学特征，口服生物利用度为40.5％。在HCT-116异种移植体内模型中，17c通过诱导自噬细胞死亡并抑制IL6-JAK-STAT信号通路，对肿瘤的生长表现出有效的抑制作用。我们的结果表明，BRD4-HDAC双重抑制可能是CRC的一种有吸引力的治疗策略。

  DOI：

  10.1021/acs.jmedchem.9b02178

文献信息

• Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines – Their potential as adenosine receptor ligands
  作者：B. Sirisha、B. Narsaiah、T. Yakaiah、G. Gayatri、G. Narahari Sastry、M. Raghu Prasad、A. Raghuram Rao

  DOI：10.1016/j.ejmech.2009.12.075

  日期：2010.5

  A series of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines 6a-c and 7a-d was synthesized in two steps from thienopyrimidin-4-ones 2 through O- and N-propargylated regioisomers 3a-i and 4a-i respectively. Compound 2 was reacted with propargyl bromide to form O- and N-propargylated regioisomers 3 and 4 in definite proportions. Each regioisomer was separated and independently subjected to [3 + 2] cycloaddition using perfluoroalkyl azides through Click reaction under Sharpless conditions and obtained exclusively anti product in each case. The formation of two regioisomers in the first step and single anti addition product in the next step could be explained based on computational studies carried out at B3LYP/6-31G(d) level of theory. Results of Fukui function indices at the reactive centers are in accordance with the observations. On evaluation of the synthesized molecules for their binding affinities towards adenosine receptors, 4d and 4f were found to be selective to A(1) over A(2A) receptors. (C) 2010 Elsevier Masson SAS. All rights reserved.
• Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer
  作者：Liang Ouyang、Lan Zhang、Jie Liu、Leilei Fu、Dahong Yao、Yuqian Zhao、Shouyue Zhang、Guan Wang、Gu He、Bo Liu

  DOI：10.1021/acs.jmedchem.7b00275

  日期：2017.12.28

  Upon the basis of The Cancer Genome Atlas (TCGA) data set, we identified that several autophagy-related proteins such as AMP-activated protein kinase (AMPK) were remarkably downregulated in breast cancer. Combined with coimmunoprecipitation assay, we demonstrated that BRD4 might interact with AMPK. After analyses of the pharmacophore and WPF interaction optimization, we designed a small-molecule inhibitor of BRD4, 9f (FL-411) which was validated by cocrystal structure with BD1 of BRD4. Subsequently, 9f was discovered to induce ATG5-dependent autophagy-associated cell death (ACD) by blocking BRD4-AMPK interaction and thus activating AMPK-mTOR-ULK1-modulated autophagic pathway in breast cancer cells. Interestingly, the iTRAQ-based proteomics analyses revealed that 9f induced ACD pathways involved in HMGB1, VDAC1/2, and eEF2. Moreover, 9f displayed a therapeutic potential on both breast cancer xenograft mouse and zebrafish models. Together, these results demonstrate that a novel small-molecule inhibitor of BRD4 induces BRD4-AMPK-modulated ACD in breast cancer, which may provide a candidate drug for future cancer therapy.
• Ried,W.; Giesse,R., Justus Liebigs Annalen der Chemie, 1968, vol. 713, p. 143 - 148
  作者：Ried,W.、Giesse,R.

  DOI：——

  日期：——
• Perrissin; Favre; Luu-Duc, European Journal of Medicinal Chemistry, 1984, vol. 19, # 5, p. 420 - 424
  作者：Perrissin、Favre、Luu-Duc、et al.

  DOI：——

  日期：——
• Haubold; Pech; Bernath, Pharmazie, 1983, vol. 38, # 4, p. 269 - 270
  作者：Haubold、Pech、Bernath、et al.

  DOI：——

  日期：——